Document is current
Any future updates will be listed below
-
Authors
Senna, Maryanne
Hanna, Sameh
Ueki, Rie
Zhang, Xingqi
Aguh, Crystal
Piraccini, Bianca Maria
Wajsbrot, Dalia
Nagy, Edward
Sadrarhami, Mojgan
Chen, Simon
Wolk, Robert
Tran, Helen
Lejeune, Alexandre
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03732807 at ClinicalTrials.govnct04006457 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
https://doi.org/10.1007/s40257-024-00899-4
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
https://doi.org/10.1007/s13555-024-01260-7
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-026-01062-x
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
nct04517864 at ClinicalTrials.govDocuments that mention this clinical trial
Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
https://doi.org/10.1007/s13555-025-01648-z
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-026-01062-x
nct02974868 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-026-01062-x
Documents that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-026-01062-x
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
New drugs under investigation for the treatment of alopecias
https://doi.org/10.1080/13543784.2019.1568989
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 28 May 2026
Accepted: 8 July 2026
First Online: 22 July 2026
Declarations
Conflict of Interest: Maryanne Senna is a member on a scientific advisory board and/or consultant for Eli Lilly, BiologicsMD, Pfizer Inc, Arena Pharmaceuticals, Inmagene, Kintor, and L’Oréal; is a speaker for Eli Lilly and Pfizer Inc; received research funding from Eli Lilly, Concert, Clarity, Follica, LEO Pharma, and Santiste; is a member on the board of directors for the Scarring Alopecia Foundation and American Hair Research Society; and co-director of the CorEvitas AA Registry. Sameh Hanna is a clinical trialist for AbbVie, Lilly, Lumenis, and Pfizer Inc and received honoraria for speaking/consulting from AbbVie, Lilly, and Pfizer Inc. Rie Ueki is a clinical trial investigator for Pfizer Inc. Xingqi Zhang has no conflict of interest. Crystal Aguh serves as a consultant for Pfizer, Lilly, and Myovant Sciences. She is on the advisory board for Olaplex, Veradermics, and CPSkin Health. She is the editor of the UpToDate section on Central Centrifugal Cicatricial Alopecia, for which she receives royalties. Her research program is supported through an educational grant by Lilly. Bianca Maria Piraccini received honoraria for participation in advisory boards, being a speaker, and/or being a consultant for Almirall, Pfizer Inc, Eli Lilly, Pierre Fabre-Ducray, Cantabria-Difa Cooper, Dercos-L’Oreal, ISDIN, and Legacy Healthcare. Edward Nagy, Mojgan Sadrarhami, Simon Chen, Robert Wolk, Alexandre Lejeune, and Helen Tran are employees of and hold stock or stock options in Pfizer.
Ethics Approval: Ethics approval was obtained for individual studies included in the analysis. The study was performed in accordance with the ethical standards as provided in the Declaration of Helsinki.
Consent to Participate: Informed consent was obtained from all participants of the individual studies included in this analysis.
Patient Consent to Publish: Patients signed informed consent regarding publishing their data.
Data Availability: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See for more information.
Code Availability: Not applicable.
Author Contributions: All authors contributed to the concept and design of the study, to data analysis and interpretation, to critical revision of the publication, and all authors read and approved the final manuscript.
